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Energy release from cellular storage is mandatory for
survival during fasting. This is achieved through lipol-
ysis and liver gluconeogenesis. We show here that in
the mouse, gut-derived serotonin (GDS) is upregu-
lated during fasting and that it favors both mecha-
nisms. In adipocytes, GDS signals through the
Htr2b receptor to favor lipolysis by increasing phos-
phorylation and activity of hormone-sensitive lipase.
In hepatocytes, GDS signaling through Htr2b pro-
motes gluconeogenesis by enhancing activity of
two rate-limiting gluconeogenic enzymes, FBPase
and G6Pase. In addition, GDS signaling in hepato-
cytes prevents glucose uptake in a Glut2-dependent
manner, thereby further favoring maintenance of
blood glucose levels. As a result, inhibition of GDS
synthesis can improve glucose intolerance caused
by high-fat diet. Hence, GDS opposes deleterious
consequences of food deprivation by favoring lipol-
ysis and liver gluconeogenesis while preventing
glucose uptake by hepatocytes. As a result, pharma-
cological inhibition of its synthesis may contribute to
improve type 2 diabetes.
INTRODUCTION
The ability to survive during food deprivation has been a constant
necessity for living organisms throughout evolution. In verte-
brates most of the energy stores are located in adipose tissue
and liver. Hence, these two organs are the main providers of
energy to the rest of the body during fasting. Adipose tissue
releases FFAs and glycerol in the process of lipolysis (Rosen
and Spiegelman, 2000; Zechner et al., 2012), while liver
produces ketone bodies, releases triglycerides, and maintains
glucose levels mainly through gluconeogenesis (Lin and Accili,
2011; Rosen and Spiegelman, 2000). Given the prime impor-
tance of lipolysis and gluconeogenesis for adaptation to fasting,
these processes need to be tightly regulated.
The best-established regulation of lipolysis is exerted on the
one hand by insulin that inhibits it (Saltiel and Kahn, 2001) and
on the other hand by glucocorticoids and the sympathetic
nervous system that favor it (Vegiopoulos and Herzig, 2007;588 Cell Metabolism 16, 588–600, November 7, 2012 ª2012 ElsevierZechner et al., 2012). In addition, FGF21, glucagon, and ghrelin
have been identified as potential regulators of lipolysis (Inagaki
et al., 2007; Perea et al., 1995; Vestergaard et al., 2008).
However, both the physiological importance of lipolysis and
the identification in recent years through mouse genetics of
novel regulators of this process suggest that additional, yet to
be identified hormones regulating positively or negatively this
survival function may exist.
A second mechanism implicated in the adaptation to food
deprivation is liver de novo glucose synthesis, or gluconeogen-
esis. This process can be initiated from multiple substrates
such as pyruvate, glycerol, amino acids, or lactate (Lin and Accili,
2011). Like lipolysis, this physiological process is tightly regu-
lated by hormonal inputs, with insulin inhibiting it and glucagon,
glucocorticoids, catecholamines, and FGF21 favoring it (Lin and
Accili, 2011; Potthoff et al., 2009; Vegiopoulos and Herzig, 2007).
Just as it is the case for lipolysis, it is likely that a systematic
analysis of available mutant mouse strains lacking a given circu-
lating molecule or receptor may identify novel regulators of this
process.
Serotonin is a bioamine derived from tryptophan that is highly
conserved throughout evolution (Berger et al., 2009). In verte-
brates there are two pools of serotonin, one made in neurons
of the brainstem and one made in the periphery, mainly, but
not only, in enterochromaffin cells of the gut. In those two
compartments, serotonin biosynthesis is initiated by a different
rate-limiting enzyme, tryptophan hydroxylase 1 (Tph1) in the
periphery and tryptophan hydroxylase 2 (Tph2) in the brain.
Since serotonin does not cross the blood-brain barrier, it is
believed that each pool of serotonin has a discrete set of func-
tions (Berger et al., 2009), although some neurons of the hypo-
thalamus may be accessible to peripheral molecules that other-
wise do not cross the blood-brain barrier. While brain-derived
serotonin is amultifunctional neurotransmitter, gut-derived sero-
tonin (GDS) has emerged recently as a hormone able to regulate
bone formation, erythropoiesis, and regenerative processes
(Amireault et al., 2011; Dees et al., 2011; Fligny et al., 2008;
Lesurtel et al., 2006; Yadav et al., 2008). These functions of
GDS raise the possibility that it may have additional endocrine
roles. In particular, considering the regulation of bone formation
by GDS, it is important to test if GDS regulates any aspect of
energy metabolism as several other hormones affecting bone
mass do (Ducy et al., 1996; Lee et al., 2007; Wei et al., 2012).
In this study we show that food deprivation promotes
synthesis of GDS, which in turn favors both lipolysis and liver
gluconeogenesis by signaling, in adipocytes and hepatocytes,Inc.
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uptake by hepatocytes, thereby further contributing to maintain-
ing normal blood glucose levels. Taking advantage of the avail-
ability of a small-molecule inhibitor of GDS synthesis, we also
provide pharmacological evidence that decreasing its synthesis
has beneficial effects in type 2 diabetic mice.
RESULTS
GDS Promotes Lipid Mobilization upon Fasting
To expand our knowledge about GDS biology, we asked how its
synthesis is regulated. Given the role of food intake during bone
formation and the regulation of bone formation by GDS (Black
et al., 2001; Yadav et al., 2008), we asked whether fasting affects
GDS synthesis.
As shown in Figures 1A and 1B, Tph1 expression in the gut and
plasma serotonin levels were both significantly increased in
fasted WT mice at all time points analyzed. Plasma serotonin
levels reached 24 mM upon 48 hr of fasting. Although the
increase in Tph1 expression in the duodenum was modest
upon fasting, it was specific, since its expression in adipose
tissue was nearly 300-fold lower than in duodenum. Likewise,
expression of Tph2, the rate-limiting enzyme in brain serotonin
synthesis, was 200-fold lower in adipose tissue than in the brain-
stem (Figure S1I). The increase in circulating serotonin levels
occurred before and was not of lesser amplitude than the one
of glucagon (Figure 1C), a major determinant of the adaptation
to fasting (Unger and Cherrington, 2012). Since metabolic
adaptation to fasting relies, in part, on lipolysis, we tested
whether GDS is a physiological regulator of lipolysis by analyzing
mice lacking tryptophan hydroxylase 1 (Tph1), the initial and
rate-limiting enzyme in GDS biosynthesis, only in the gut
(Tph1gutD/D mice) (Figures S1A and S1B) (Yadav et al., 2008).
Body, organ, and fad pad weights as well as food intake were
similar in Tph1gutD/D and Tph1fl/fl mice fed ad libitum a normal
diet (Figures S1C and S1D). Likewise, circulating triglyceride
levels and expression of the crucial regulators of fat absorption,
FIAF and LPL (Ba¨ckhed et al., 2004), in intestine and adipose
tissue were not changed in fed and fasted Tph1gutD/Dmice (Fig-
ure 1G and Figures S1F and S2C). In contrast, fasted Tph1gutD/D
mice could not increase their circulating levels of glycerol as
Tph1 fl/fl littermates did (Figure 1D). The lack of increase of circu-
lating glycerol levels in Tph1 fl/fl mice after 4 hr of fasting
compared to what they are after 48 hr of fasting reflects the
fact that the rate of lipolysis is much higher at that latter time
point. We verified that the food content in stomach, duodenum,
jejunum, and ileum was significantly decreased after a 4 hr fast
(Figure S1G). Tph1gutD/D mice did increase their circulating
levels of FFAs during a prolonged fasting, but this increase re-
mained significantly weaker than the one seen in Tph1 fl/fl litter-
mate controls (Figure 1E). Likewise, GDS deficiency blunted the
increase of plasma ketone bodies such as b-hydroxybutyrate
that normally occurs during fasting (Figure 1F). The rate of glyc-
erol and FFA clearance in Tph1gutD/D and Tph1 fl/flmice was the
same (Figures S1J and S1K), and the VillinCre transgene did not
alter glycerol, FFA, and b-hydroxybutyrate circulating levels in
fed or fasted mice (Figures S3A–S3C). Hence, in absence of
GDS, the levels of three main energetic substrates during fasting
are blunted.Cell MConsistent with their failure to induce appropriate lipolysis,
Tph1gutD/D mice fasted for 48 hr lost significantly less body
weight and less fat and displayed larger adipocytes than Tph1
fl/flmice (Figures 1H–1L and Figure S2A). Respiratory exchange
rate was increased in fasted Tph1gutD/D compared to littermate
Tph1 fl/fl mice, while energy expenditure was similar (Fig-
ure S2B). Circulating levels of insulin and leptin were normal in
fed and fasted Tph1gutD/D mice (Figures S2D and S2E), and
there was no evidence of transformation of white fat into brown
fat in Tph1gutD/D mice as reported for FGF21-deficient animals
(Fisher et al., 2012) (Figure S2C).
To assess the importance GDS regulation of lipolysis, we next
asked whether enhancing peripheral serotonin signaling in vivo
in WT mice would promote lipolysis. Implanting subcutaneously
serotonin-releasing pellets in WT mice (350 ng/hr/animal for
60 days) led to an increase of circulating levels of serotonin of
approximately 2.5-fold (Figure S2F), resulting in a significant
increase in circulating levels of both glycerol and FFAs, an
increase that was further enhanced following a 4 hr-long fasting
period (Figures 1M and 1N). Similar results were obtained with
single-shot injections of serotonin (Figures 1O and 1P). Taken
together, these loss- and gain-of-function experiments concur
to indicate that GDS is a positive regulator of lipolysis. That abro-
gating GDS synthesis inhibited almost completely the increase
of glycerol release during lipolysis, but only partially FFA release,
is fully consistent with the notion that GDS is by no means the
only regulator of lipolysis.
We are aware that in the conditions of this experiment, sero-
tonin might have evoked other responses that may confound
interpretation. This is why this experiment was repeated once
the appropriate serotonin receptor was identified and deleted
in a cell-specific manner (see below).
GDS Promotes Lipolysis by Acting through Htr2b
Receptor on Adipocytes
Wenext askedwhetherGDSpromotes lipolysis by acting directly
on adipocytes. First we treated epididymal and subcutaneous
fat pads with increasing amounts of serotonin. This treatment
increased significantly and in a dose-dependent manner release
of glycerol and, to an even larger extent, of FFAs, suggesting that
serotonin acts directly on adipose tissue to favor lipolysis
(Figures 2A and 2B and Figures S4A and S4B). Next we isolated
epigonadal adipocytes and treated them with serotonin. That
serotonin increased the release of glycerol and FFAs in isolated
adipocytes indicated that the adipocyte is a cell type on which
serotonin acts to promote lipolysis (Figures S4C and S4D).
In view of these results, we sought to identify serotonin
receptor expressed in adipocytes. Among the 14 known sero-
tonin receptors (Berger et al., 2009), Htr2b was by far the most
highly expressed in mouse adipocytes, and its expression in
white adipose tissue markedly increased upon fasting (Figures
S4E and S4F and Figure 2C). Given this pattern of expression,
we tested whether Htr2b mediates serotonin regulation of lipol-
ysis in vivo by analyzing mice lacking this receptor only in adipo-
cytes (Htr2bfatD/Dmice). Prior to studying thesemutantmice, we
verified that Htr2b had been deleted in adipocytes but not in
macrophages (Figure S4G).
Like Tph1gutD/D mice, Htr2bfatD/D mice displayed normal
body and organ weight when fed a normal diet ad libitum.etabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc. 589
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Figure 1. GDS Is Required for Fasting-Induced Lipolysis
(A) Relative expression levels of Tph1 in duodenum from mice fasted for indicated times (nR 5).
(B and C) Plasma levels of serotonin (B) and glucagon (C) in mice fasted for indicated times (nR 5).
(D–G) Plasma levels of glycerol (D), FFAs (E), b-hydroxybutyrate (F), and triglycerides (G) in mice of indicated genotypes fasted for indicated times (nR 7).
(H) Percent of fat content in fed and fasted mice of indicated genotypes measured by magnetic resonance imaging (MRI) (nR 5).
(I) Percent of fat content loss during 48 hr fasting in relation to initial fat content of each animal; average of five mice of Tph1f/f and Tph1gutD/D genotype.
(J) Epigonadal fat pad weight to body weight ratio in fed and fasted Tph1f/f and Tph1gutD/D mice (nR 6).
(K) Histology of fat pad from fed and 48 hr fasted Tph1f/f and Tph1gutD/D mice (nR 5).
(L–N) Average size of adipocytes from fat pad of fed and 48 hr fasted Tph1f/f and Tph1gutD/Dmice (L, nR 5). Plasma levels of glycerol (M) and FFAs (N) in mice
with implanted placebo or serotonin-releasing pellets fasted for indicated time (nR 8).
(O and P) Plasma levels of glycerol (O) and FFAs (P) at indicated time points after i.p. injection of serotonin (doses in mg/kg BW) (nR 5). Data represented as
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
Cell Metabolism
Gut Serotonin Promotes Adaptation to Fasting
590 Cell Metabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc.
Cell Metabolism
Gut Serotonin Promotes Adaptation to FastingLikewise, their circulating levels of insulin, leptin, and triglycer-
ides were normal in fed and fasted conditions (Figures S4I–
S4M). Upon fasting, however, we did not observe in Htr2bfatD/D
mice the increase in circulating glycerol levels seen in Htr2b fl/fl
control mice, and the increase in FFAs and b-hydroxybutyrate
circulating levels was significantly weaker in Htr2bfatD/D than
in Htr2b fl/fl mice (Figures 2D–2F). Moreover, Htr2bfatD/D
mice maintained bigger fat pads and larger adipocytes after a
48 hr-long fasting than Htr2b fl/flmice did (Figure 2I and Figures
S4N and S4O). Hence, the metabolic profile of Htr2bfatD/Dmice
is similar to the one observed in Tph1gutD/D mice. The aP2-Cre
transgene did not affect glycerol, FFAs, and b-hydroxybutyrate
levels when compared to littermate WT mice, whether in fed or
fasted conditions (Figures S3H–S3J).
Since aP2-Cre deleted Htr2b in hypothalamus (Figure S4G),
we repeated this experiment using a different Cre driver, the
Adiponectin-Cre that did not remove Htr2b in cell types other
than the adipocytes and in particular not in hypothalamic neurons
(Eguchi et al., 2011) (Figure S4H). Glycerol levels did not increase
either upon fasting, and the increase in FFAs levels was also
blunted in Adiponectin-Cre;Htr2bfl/fl mice (Figures 2G and 2H).
In agreement with these loss-of-function results, implantation
of serotonin-releasing pellets did not increase glycerol and
FFA circulating levels in Htr2bfatD/D mice as it did in Htr2b fl/fl
littermates (Figures 2J and 2K). Moreover, in cell culture studies,
while isoproterenol, a positive control, promoted the release of
FFAs and glycerol equally well in WT and Htr2b-deficient
adipose tissue explants, serotonin increased the release of
FFAs and glycerol in WT but not in Htr2b-deficient explants
(Figures 2L and 2M). Taken together this set of experiments indi-
cates that GDS favors lipolysis by signaling through the Htr2b
receptor expressed in adipocytes.
Tobegindeciphering themolecularmodeof actionof serotonin
in adipocytes downstream of Htr2b, we analyzed expression,
accumulation, and phosphorylation of key lipolytic enzymes
(Haemmerle et al., 2006; Martinez-Botas et al., 2000; Osuga
et al., 2000). While serotonin did not alter expression or accumu-
lation of enzymes involved in lipolysis, it favored, ex vivo, phos-
phorylation of hormone-sensitive lipase (HSL) on serine 563 and
660 in an Htr2b-dependent manner (Figure 2N and Figure S4P).
These two phosphorylation events have been shown to enhance
HSL activity (Anthonsen et al., 1998; Greenberg et al., 2001). To
determine if this regulation of phosphorylation of HSL by sero-
tonin occurs also in vivo, we analyzed Htr2bfatD/D and Htr2b
fl/fl mice that had been fasted for 48 hr. As shown in Figure 2O,
phosphorylation of HSL was decreased in Htr2bfatD/D adipose
tissue, indicating that a signaling event elicited by serotonin in
adipocytes is to favor HSL phosphorylation, an event that should
increase HSL activity. Since both HSL and ATGL promote lipol-
ysis, we tested whether serotonin affects ATGL localization, but
failed to observe any effect of serotonin on its translocation to
lipid droplets (Figure S4Q). In view of these data, we conclude
that one mechanism whereby serotonin favors lipolysis is phos-
phorylation of HSL on residues serine 563 and serine 660, two
events viewed as activating HSL (Djouder et al., 2010; Iwata
et al., 2012). We cannot exclude, however, that serotonin may
also increase activation of ATGL and perilipin, two aspects of
lipolysis that could not be tested due to the lack of reliable
reagents, or other components of lipolytic machinery.Cell MGDS Promotes Liver Gluconeogenesis
Glycerol is a substrate for liver gluconeogenesis upon fasting (Lin
and Accili, 2011); thus the results presented above implied that
GDS should promote gluconeogenesis because of its ability to
increase glycerol levels.
Glycerol injections, however, did not increase circulating
glucose levels to the same extent in Tph1gutD/D as in Tph1 fl/fl
control mice (Figure 3A). Moreover, injections of pyruvate, the
initial substrate in liver gluconeogenesis, whose circulating levels
are not influenced by lipolysis, also failed to increase blood
glucose levels in Tph1gutD/Dmice as they did in Tph1 fl/fl control
mice (Figure 3B). Villin-Cre transgenic mice did not show any
alteration of gluconeogenesis compared to littermate controls
after glycerol or pyruvate injections (Figures S3D and S3E).
These results implied that the favorable influence of GDS on liver
gluconeogenesis is not a mere consequence of its upregulation
of lipolysis. Indeed, in WT mice implanted with serotonin-
releasing pellets, which increased plasma serotonin levels 2.5
times (Figure S2F), glycerol injection increased blood glucose
to higher levels than in control mice (Figure 3C). Similar results
were obtained following a single injection of serotonin (10 mg/g
BW) in both Tph1 fl/fl and Tph1gutD/D mice (Figure 3D).
To further test if GDS can induce gluconeogenesis from
endogenous substrates, we measured hepatic glucose produc-
tion (HGP) in Tph1gutD/D and Tph1 fl/fl mice in conditions of
hyperinsulinemic-euglycemic clamps and observed that HGP
was reduced more than 2-fold in Tph1gut D/D mice fasted for
4 hr (Figures 3E and 3F). Although the effect that insulin infusion
might have on serotonin levels was not measured in this assay,
this result supports the contention that GDS is a positive regu-
lator of liver gluconeogenesis. We next tested if serotonin acts
directly on hepatocytes for that purpose. When added to hepa-
tocyte cultures, serotonin (10–50 mM) stimulated conversion of
glycerol as well as lactate/pyruvate to glucose like the positive
control glucagon did (Figure 3G). That serotonin decreased the
rate of glucose production in the absence of substrate suggests
that it specifically promotes gluconeogenesis. Taken together,
our results indicate that GDS is necessary but not sufficient for
proper induction of gluconeogenesis upon fasting. That Tph1
deletion does not result in a decrease of fasting glucose levels
is consistent with the fact that other hormones also regulate
gluconeogenesis during fasting (Lin and Accili, 2011; Vegiopou-
los and Herzig, 2007).
GDS Inhibits Glucose Uptake by Hepatocytes
During fasting, glucose uptake by hepatocytes is partially
blocked (Wahren and Ekberg, 2007). To test if serotonin also
modulates this aspect of adaptation to fasting, we subjected
fasted Tph1gutD/D and control mice to glucose tolerance tests.
Clearance of a glucose load was significantly improved in
Tph1gutD/D compared to Tph1 fl/fl mice (Figure 3H) and was
not affected by expression of the VilinCre transgene (Figure S3F).
Importantly, Tph1gutD/D mice showed normal glucose-stimu-
lated insulin secretion at basal conditions (Figure 3I). Conversely,
WT mice implanted with serotonin-releasing pellets, which
increased plasma serotonin levels 2.5 times (Figure S2G),
showed impaired glucose clearance during glucose tolerance
test compared to placebo-implanted controls (Figure 3J). Similar
results were obtained after a single injection of serotonin (10 mg/getabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc. 591
AE F G H
I
M N O
J K L
B C D
Figure 2. GDS Favors Lipolysis through Htr2b Receptor Expressed in Adipocytes
(A and B) Glycerol (A) and FFAs (B) release from mouse epigonadal fat explants stimulated with indicated doses of serotonin (nR 5).
(C) Relative expression of indicated serotonin receptors in adipose tissue of fed and fasted mice.
(D–F) Plasma levels of glycerol (D), FFAs (E), and b-hydroxybutyrate (F) in mice lacking Htr2b in adipose tissue (deletion by aP2-Cre, indicated on graphs
Htr2bfatD/D [aP2]) fasted for indicated times (nR 20).
(G and H) Plasma levels of glycerol (G) and FFAs (H) in mice lacking Htr2b in adipose tissue (deletion by Adiponectin-Cre, indicated on graphs Htr2bfatD/D [Aq])
fasted for indicated times (nR 6).
(I) Epigonadal fat pad weight to body weight ratio in fed and fasted Htr2bf/f and Htr2bfatD/D (aP2) mice (nR 12).
(J and K) Glycerol (J) and FFA levels (K) in Htr2bf/f and Htr2bfatD/D (aP2) mice implanted with serotonin-releasing pellets.
(L andM) Glycerol (L) and FFAs (M) release from epigonadal fat explants isolated fromHtr2bf/f andHtr2bfatD/D (aP2) mice and stimulated with 50 mMserotonin or
1 mM isoproterenol (n = 5).
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over, stimulation of hepatocytes by serotonin (10–50 mM)
reduced glucose uptake by 40% (Figure 3L). These results indi-
cate that GDS regulation of glucose uptake by hepatocytes and
glucose clearance in Tph1gutD/Dmice occur because of a direct
action of this hormone on liver. That these results obtained
through the analysis of cell-specific deletion differ from those
obtained when analyzing mice lacking Tph1 in all cells (Fig-
ure 3M) (Paulmann et al., 2009) implies that Tph1 has additional
functions in other cell types.GDS Promotes Liver Gluconeogenesis through Htr2b
in Hepatocytes
As is the case in adipocytes, Htr2b is by far the most highly ex-
pressed serotonin receptor in the liver, where its expression
also increases upon fasting (Figures 4A and 4B). Therefore, we
tested whether Htr2b mediates serotonin regulation of hepatic
gluconeogenesis through the analysis of mutant mice lacking
this receptor only in hepatocytes (Htr2bliverD/D mice). Prior to
studying thesemutant mice, we verified thatHtr2b had been effi-
ciently removed from hepatocytes but not from other cell types
(Figure S6A).
When fed a normal diet ad libitum, Htr2bliverD/D mice had
normal body and organ weights, insulin, leptin, triglycerides,
and FFA circulating levels (Figures S6B–S6G). However, glucose
production measured following glycerol or pyruvate injections
was attenuated in Htr2bliverD/D compared to Htr2b fl/fl mice
(Figures 4C and 4D). Albumin-Cre transgenic mice and littermate
control animals responded similarly to glycerol and pyruvate
challenge (Figures S3R and S3S). Two additional experiments
support the notion that Htr2b expression in hepatocytes medi-
ates GDS regulation of liver gluconeogenesis by GDS. First,
serotonin could not induce glucose production from glycerol
or pyruvate/lactate when added to Htr2bD/D hepatocytes,
whereas it did when added to Htr2b fl/fl hepatocytes (Fig-
ure 4E). Second, implantation of serotonin-releasing pellets did
not induce gluconeogenesis in Htr2bliverD/D mice as it did in
Htr2b fl/flmice (Figure 4F). That the decrease of glucose produc-
tion by serotonin in absence of substrate was not affected by
Htr2b deletion suggests that another receptor mediates this
function of GDS in liver (Figure 4E).
In an effort to elucidate how GDS could promote liver gluco-
neogenesis, we analyzed gene expression and protein levels of
key determinants of glycerol-dependant gluconeogenesis such
as FBPase, G6Pase, glycerol kinase, and aquaporin 9 (Lin and
Accili, 2011), but failed to observe any significant changes in
Htr2bliverD/Dmice (Figures S6H and S6I). In contrast, when enzy-
matic activities were measured through classical bioassays
(Alegre et al., 1988; Reyes et al., 1987), we observed that the
activity of two rate-limiting enzymes for gluconeogenesis,
FBPase and G6Pase, was decreased 20% and 25%, respec-
tively, in Htr2bliverD/Dmice (Figures 4K and 4L). Moreover, sero-
tonin (10–50 mM) treatment of isolated hepatocytes significantly(N) Western blot analysis of expression and activation of indicated proteins in fat
50 mM serotonin.
(O) Western blot analysis of expression and activation of indicated proteins in fat p
represented as mean ± SEM, *p < 0.05, ***p < 0.001.
Cell Mincreased activity of both G6Pase and FBPase (Figures 4I and
4J). These results suggest that one mechanism whereby sero-
tonin favors gluconeogenesis is by enhancing activity of these
two enzymes.
GDS Inhibits Glucose Uptake through Htr2b Receptor
in Hepatocytes
To test if GDSblocks glucose uptake in hepatocytes by acting on
the Htr2b receptor, we subjected Htr2bliverD/D mice to glucose
tolerance test. Glucose clearance in Htr2bliverD/D mice was
markedly increased compared to Htr2b fl/fl mice (Figure 5A),
while Albumin-Cre transgenic mice and littermate control
animals responded similarly to glucose challenge (Figure S3T).
Implantation of serotonin-releasing pellets did not induce
glucose intolerance in Htr2bliverD/D mice as it did in Htr2b fl/fl
mice (Figure 5B), and serotonin failed to block glucose uptake
in Htr2b-deficient hepatocytes (Figure 5C). Taken together these
data indicate that GDS blocks glucose uptake in hepatocytes by
acting on Htr2b receptor.
To unravel the molecular mechanisms underlying serotonin
inhibition of glucose uptake, we first examined expression and
localization of two major glucose transporters (Gluts) in hepato-
cytes, Glut1 and Glut2 (Gonza´lez-Rodriguez et al., 2008). Sero-
tonin stimulation of hepatocytes isolated from Htr2b fl/fl or
Htr2bliverD/D mice did not alter subcellular localization of these
two transporters (Figure 5D), but it decreased Glut2 abundance
since the intensity of the Glut2 staining decreased markedly in
serotonin-stimulated WT but not Htr2b-deficient hepatocytes.
Moreover, Glut2 levels were upregulated in Htr2bliverD/D com-
pared to Htr2b fl/fl livers during fasting while Glut1 levels were
unaffected (Figure 5E). Glut1 and Glut2 expression was not
changed in Htr2bliverD/D (Figure S6I). Activity of glucokinase,
the first rate-limiting enzyme in hepatic glucose utilization (Mat-
schinsky, 2009), was also significantly increased in fasted
Htr2bliverD/D mice (Figure 5F). These data suggest that GDS
suppresses glucose uptake by hepatocytes in part by promoting
Glut2 degradation and suppressing glucokinase activity.
Inhibition of GDS Synthesis Protects against Diet-
Induced Type 2 Diabetes
Elevation of FFA levels can contribute to the development of
insulin resistance, especially in conditions of hyperglycemia
(Saltiel and Kahn, 2001; Samuel and Shulman, 2012). This
notion, along with the positive effect of GDS on liver gluconeo-
genesis, led us to ask whether abrogating GDS synthesis or
signaling in adipocytes will influence tolerance to insulin.
Insulin tolerance, measured by insulin tolerance test (ITT) or
glucose infusion rates during hyperinsulinemic-euglycemic
clamps, was significantly improved in Tph1gutD/D and
Htr2bfatD/D mice compared to control animals (Figures 6A,
6B, and 3F). Likewise, Tph1gutD/D and Htr2bliverD/D mice
were significantly more tolerant to a glucose challenge than
Tph1 fl/fl or Htr2b fl/fl littermates (Figures 3F and 5A), whileexplants isolated from Htr2bf/f and Htr2bfatD/D (aP2) mice and stimulated with
ads isolated from Htr2bf/f and Htr2bfatD/D (aP2) mice fasted for 48 hr. Data are
etabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc. 593
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Figure 3. GDS Promotes Gluconeogenesis in Liver
(A) Glycerol-evoked glucose production in Tph1f/f and Tph1gutD/D mice (nR 8).
(B) Pyruvate tolerance test in Tph1f/f and Tph1gutD/D mice (nR 8).
(C) Glycerol tolerance test in mice with implanted placebo or serotonin-releasing pellets (nR 8).
Cell Metabolism
Gut Serotonin Promotes Adaptation to Fasting
594 Cell Metabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc.
A B C
D E F
G H I J
Figure 4. GDS Promotes Gluconeogenesis in Liver by Signaling through the Htr2b Receptor
(A) Relative expression of indicated serotonin receptors in primary mouse hepatocytes. Red color indicates receptors for which the transcript was detected.
(B) Relative expression of indicated serotonin receptors in liver of fed and fasted mice.
(C) Glycerol tolerance test in Htr2bf/f and Htr2bliverD/D mice (nR 7).
(D) Pyruvate tolerance test in Htr2bf/f and Htr2bliverD/D mice (nR 7).
(E) Production of glucose from indicted substrates by hepatocytes isolated from Htr2bf/f and Htr2bliverD/D mice and stimulated by 50 mM serotonin (n = 5).
(F) Glycerol tolerance test in Htr2bf/f and Htr2bliverD/D mice implanted with placebo or serotonin-releasing pellets (nR 6).
(G and H) Normalized FBPase (G) and G6Pase (H) activity in livers of fasted Htr2bf/f and Htr2bliverD/D mice (nR 6).
(I and J) Normalized FBPase (I) and G6Pase (J) activity in isolated hepatocytes stimulated with indicated doses of serotonin (n R 3). Data are represented as
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
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Gut Serotonin Promotes Adaptation to FastingCre-expressing mouse lines tested (VillinCre, aP2Cre, AlbCre)
responded to insulin and glucose challenge like WT mice
(Figures S2F, S2G, S2M, S2N, S2T, and S2U).
The results presented above implied that decreasing GDS
synthesis might attenuate the severity of type 2 diabetes,(D) Glycerol-evoked glucose production in Tph1f/f and Tph1gutD/D mice injected
(E and F) Hepatic glucose production (E) and glucose infusion rate (F) during hyp
(G) Production of glucose from indicated substrates by primary hepatocytes stim
(H) Glucose tolerance test in Tph1f/f and Tph1gutD/D mice (nR 7).
(I) Plasma insulin levels during glucose tolerance test in Tph1f/f and Tph1gutD/D
(J) Glucose tolerance test in mice with implanted placebo or serotonin-releasing
(K) Glucose tolerance test in Tph1f/f and Tph1gutD/D mice injected with serotoni
(L) Glucose uptake in primary hepatocytes stimulated with indicated doses of se
(M) Glucose tolerance test in Tph1+/+ and Tph1/ mice (nR 3). Data are repr
Cell Ma hypothesis tested genetically. Tph1gutD/D and Tph1fl/fl mice
were fed a high-fat diet (HFD) for 12 weeks to induce obesity
and glucose intolerance. This resulted in a two-fold increase in
body weight gain in Tph1gutD/D and Tph1fl/fl mice compared
to mice of the same genotype fed normal diet (Figure 6D). Bothwith serotonin (10 mg/kg BW) 90 min before the test (nR 7).
erinsulinemic-euglycemic clamp in Tph1f/f and Tph1gutD/D mice (nR 7).
ulated with indicated doses of serotonin or 100 nM glucagon (n = 5).
mice (nR 7).
pellets (nR 8).
n (10 mg/kg BW) 90 min before the test (nR 7).
rotonin.
esented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. GDS Inhibits Glucose Uptake in Liver by Signaling through the Htr2b Receptor
(A) Glucose tolerance test in Htr2bf/f and Htr2bliverD/D mice (nR 8).
(B) Glucose tolerance test in Htr2bf/f and Htr2bliverD/D mice implanted with placebo or serotonin-releasing pellets (nR 6).
(C) Relative glucose uptake in Htr2b-deficient hepatocytes stimulated with 50 mM serotonin.
(D) Immunofluorescence with antibodies against Glut1 and Glut2 on primary hepatocytes of indicated genotypes stimulated with 50 mM serotonin.
(E) Western blot analysis of expression of indicated proteins in livers from fasted Htr2bf/f and Htr2bliverD/D mice.
(F) Normalized glucokinase activity in livers of fasted Htr2bf/f and Htr2bliverD/D mice. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
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glucose than control mice fed a normal diet (Figures 6G and I). As
hypothesized, circulating glycerol levels were significantly
reduced in Tph1gutD/D mice fed HFD compared to control
mice fed the same diet, and FFA levels in Tph1gutD/D mice fed
HFD were not different than levels observed in Tph1fl/fl mice
fed a normal diet (Figures 6E and 6F). Gluconeogenesis, insulin,
and glucose tolerance were partially normalized in Tph1gutD/D
mice fed a HFD (Figures 6G–6I).
We also asked whether a small-molecule inhibitor of Tph1
activity and thereby of GDS synthesis, which does not cross
the blood brain barrier, LP533401 (Liu et al., 2008), could
improve glucose intolerance in WT mice fed a HFD. At the
dose used for this study (100 mg/kg/day) LP533401 decreased
serotonin circulating levels 80% (Figure 6J). This resulted in
a decrease in glycerol circulating levels and a normalization
of circulating FFA levels in WT mice fed HFD (Figures 6K and
6L). Insulin tolerance was also normalized while gluconeo-
genesis and glucose tolerance were significantly improved in
LP533401-treated WTmice fed HFD (Figures 6N–6P). Moreover,
when given to WT mice fed normal diet, LP533401 decreased
glycerol and FFA levels, decreased gluconeogenesis rate, and
improved glucose and insulin tolerance as in Tph1gutD/D mice
(Figures 6K–6O). Although we cannot, at the present time, rule596 Cell Metabolism 16, 588–600, November 7, 2012 ª2012 Elsevierout that LP533401, used here as a proof of principle molecule,
may have deleterious effects, we note that this small molecule
did not affect body weight gain (Figure 6J).
DISCUSSION
This study revealed that, in the mouse, GDS is a multifunctional
adaptor to food deprivation. Indeed, it favors lipolysis and
liver gluconeogenesis and inhibits glucose uptake in liver by
signaling through the same receptor, Htr2b, in adipocytes and
hepatocytes.
Regulation of Lipolysis by GDS
Lipolysis is an adaptation mechanism used by vertebrates to
survive when food is scarce. Several convergent extracellular
cues concur to increase lipolysis during fasting. One of them is
the decline in the circulating levels of insulin, a hormone that
inhibits lipolysis in the fed state (Saltiel and Kahn, 2001), while
others are positive regulators of this survival function (Inagaki
et al., 2007; Zechner et al., 2012).
We present here evidence that GDS synthesis is stimulated by
fasting and that it favors lipolysis by signaling in adipocytes.
Conversely, increasing GDS circulating levels in WT mice
increases circulating glycerol and FFA levels. Our results identifyInc.
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lipolysis. In that regard, we note that a recent high-throughput
screen identified Htr2b as a protein modulating lipid accumula-
tion in adipocytes (So¨hle et al., 2012). These observations do
not exclude the possibility that other serotonin receptors may
be implicated in this process; however, the fact that GDS fails
to promote lipolysis in Htr2b-deficient adipocytes indicates
that expression of this receptor is a critical role to mediate this
function of GDS.
Our investigation indicates that GDS favors lipolysis by
increasing the phosphorylation of hormone sensitive-lipase
(HSL) on serine residues 563 and 660, two events that increase
its activity (Anthonsen et al., 1998; Greenberg et al., 2001). This
posttranscriptional effect of GDS on HSL distinguishes it from
glucocorticoids that instead increase transcription of its gene
(Xu et al., 2009). Although we have not identified any yet, we
do not exclude the possibility that other mechanisms may also
be at work to account for GDS regulation of lipolysis.
GDS is by no means the only extracellular cue favoring lipol-
ysis (Inagaki et al., 2007; Zechner et al., 2012). This may explain
why mice with a marked decrease in GDS synthesis can still
increase, albeit less efficiently than control animals, FFA and
ketone body secretion during fasting. This illustrates the impor-
tance of lipolysis during fasting and therefore the need for
multiple levels of regulation for this process.
Regulation of Liver Glucose Metabolism by GDS
Given that glycerol may be a substrate for gluconeogenesis, it
was not surprising that by increasing lipolysis GDS would also
increase gluconeogenesis. However, the use of pyruvate as a
substrate revealed that GDS acts directly in hepatocytes to favor
gluconeogenesis. In this cell type, GDS mediates its signal also
through Htr2b.
Molecular and genetic studies identified Htr2b as a receptor
used by serotonin in hepatocytes to favor gluconeogenesis.
Other serotonin receptors are expressed in hepatocytes, albeit
at a lower level, and they may also be implicated in GDS-
mediated liver gluconeogenesis. However, that the Htr2b dele-
tion in hepatocytes disrupted liver gluconeogenesis as severely
as in Tph1gutD/Dmice indicates that this receptor plays a prom-
inent role in mediating this function of GDS. The only signaling
event we could show to be affected by serotonin signaling in
hepatocytes is an increase in the activity of two rate-limiting
enzymes needed for gluconeogenesis, FBPase and G6Pase.
Future investigations will aim at identifying signaling events
elicited by GDS in hepatocytes and affecting the activity of these
two enzymes. GDS also hampered glucose uptake by liver in part
by stimulating degradation of Glut2, which is required for this
function (Guillam et al., 1998). Since Glut2 does not appear to
affect, at least in themouse, glucose secretion from hepatocytes
nor HGP in vivo, its upregulation in the absence of GDS signaling
should not interfere with HGP (Guillam et al., 1998).
The spectrum of GDS functions described here in no way
eclipse the paramount importance of glucagon and insulin as
regulators of hepatic glucose output. We have, in fact, no
evidence suggesting that GDS is a more important regulator of
this aspect of glucose metabolism than these two hormones.
Another legitimate question raised by any metabolic study
performed in the mouse is to know whether results of theseCell Mworks have relevance to other vertebrate species. For instance,
it is possible, although it has not been tested yet in the same
condition, that GDS may exert different influence on gluconeo-
genesis in mice and dogs (Moore et al., 2004). Alternatively,
the significant differences in experimental procedures and
amounts of serotonin used may account, in part, for these differ-
ences. Of note, classical studies suggest that GDS favors lipol-
ysis in humans, too (Carlson et al., 1967). The role that GDS
may have in gluconeogenesis and glucose uptake by hepato-
cytes in humans has not been thoroughly studied yet.
Tph1 Functions in Enterochromaffin Cells
Our study revealed that ablation of Tph1 in the gut has conse-
quences on glucose metabolism different from its ablation in
all cells. As such it illustrates the importance of cell-specific
gene deletion to study complex physiological processes and to
define all functions exerted by proteins that are expressed in
several cell types. Indeed, Tph1 is expressed not only in entero-
chromaffin cells of the gut but also in b cells of the pancreas and
cells of the pineal gland (Coˆte´ et al., 2007; Kim et al., 2010). In the
pineal gland, Tph1 initiates synthesis of melatonin, a hormone
whose influence on glucose metabolism is not yet fully defined
(Rı´os-Lugo et al., 2010).
Therapeutic Implications of These Functions of GDS
In type 2 diabetes, there is often an increased lipolysis and liver
gluconeogenesis that now occurs in the fed state. This aberrant
activation of these two processes contributes to the progression
of the disease, since increasing liver gluconeogenesis leads to
hyperglycemia while raising circulating FFA levels contributes
to peripheral insulin resistance (Saltiel and Kahn, 2001; Samuel
and Shulman, 2012). Hence, the results presented here sug-
gested that decreasing GDS synthesis could ameliorate type 2
diabetes.
That decreasing GDS circulating levels through genetic or
pharmacological means improved glucose and insulin tolerance
in mutant or WT mice rendered diabetic through a HFD supports
this view, although it does not mean that decreasing GDS
synthesis could, alone, cure type 2 diabetes. The potential
importance of this last aspect of our study stems in part from
the fact that inhibition of GDS synthesis has already been shown
to cure postmenopausal osteoporosis in rodents (Yadav et al.,
2010). The steady increase in the incidence of osteoporosis
and of type 2 diabetes implies that any therapeutic means
improving the outcome of both diseases would have major
advantages.
EXPERIMENTAL PROCEDURES
Animal Experiments
Mice were housed under 12:12 light:dark cycle and chow and water were
provided ad libitum. All animals were maintained according to NIH guidelines.
The Htr2bflox/flox, Tph1flox/flox, and Villin-cre mice have been described
previously (Yadav et al., 2008). Alb-cre, aP2-cre, and Adiponectin-Cre mice
were obtained from the Jackson Laboratory.
For glucose tolerance tests, mice were fasted overnight before i.p. injection
of 2 g/kg BW d-glucose in PBS or 1 g/kg BW when mice were fed HFD. For
pyruvate tolerance tests, mice were fasted overnight and injected i.p. with
2 g/kg BW sodium pyruvate in PBS. Glycerol tolerance test (3 g/kg BW) was
performed after 4 hr fasting. For insulin tolerance test, mice were injectedetabolism 16, 588–600, November 7, 2012 ª2012 Elsevier Inc. 597
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Figure 6. Inhibition of GDS Synthesis Protects from Type 2 Diabetes
(A) Insulin tolerance test in Tph1f/f and Tph1gutD/D mice (nR 7).
(B) Insulin tolerance test in Htr2bf/f and Htr2bfatD/D mice (nR 12).
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Gut Serotonin Promotes Adaptation to Fastingwith 0.75 U/kg after 4 hr fasting. Glucose was measured by tail vein bleeds at
the indicated intervals using an ACCU-CHECK glucometer.
All fasting experiments started at 9 a.m. Measurement of glycerol, FFAs,
and b-hydroxybutyrate were performed in plasma using a triglyceride determi-
nation kit (TR0100, Sigma), NEFA-HR(2) (WAKO Diagnostics), and beta
Hydroxybutyrate Assay Kit (Abcam). Plasma concentration of serotonin and
glucagon were determined by Glucagon ELISA (Alpco, 48-GLUHU-E01) and
Serotonin (Research) ELISA, (IBL-America, IB89540).
Hyperinsulinemic-euglycemic clamp was performed in the Mouse
Phenotyping Center of University of Massachusetts Medical School. Prior
to experiments, mice were fasted for 4 hr; the insulin infusion rate was
1.25 mU/kg/min.
Enzymatic Activity Assays
FBPase, G6Pase, and glucokinase enzymatic activity assays were performed
on livers of fasted mice as described previously (Alegre et al., 1988; Reyes
et al., 1987). All reagents were obtained from Sigma.
In Vitro Lipolysis of Isolated Fat Pads
In vitro lipolysis assay was performed as described (Schweiger et al., 2006).
Briefly, epididymal (or subcutaneous, where indicated) fat pads were isolated
andwashed several times in HBSS (Sigma). Tissue pieces (25mg) were incu-
bated in DMEM medium (Invitrogen) containing 2% fatty acid free bovine
serum albumin (Sigma) at 37C for 1 hr. Fat explants were then transferred
into identical fresh medium containing serotonin (Sigma) or 10 mM isoproter-
enol as a positive control and incubated further for the indicated time points
at 37C. Afterward aliquots of medium were taken for measurements of
FFAs and glycerol, and tissue was lysed with RIPA buffer for subsequent
western blot analysis.
Statistical Analysis
Data are shown as mean values ± SEM. Analyses of significant differences
between means were performed using two-tailed Student’s t tests in case of
comparison of two groups or analysis of variance followed by Tukey’s post-
hoc test in case of multiple groups. n, number of independent cultures or
animals used. In all cases, *p < 0.05, **p < 0.01, ***p < 0.001.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.cmet.2012.09.014.
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